Single Dose of Brachytherapy Safe, Effective for Localized PC, Study Shows

Single Dose of Brachytherapy Safe, Effective for Localized PC, Study Shows
Men with low-risk prostate cancer can safely receive a single high dose of brachytherapy — a type of radiation therapy delivered directly into the tumor within a few minutes — as an alternative treatment for their condition, a study shows. After three years of treatment, 100% of men who received the treatment remained without signs of cancer recurrence, researchers said at ESTRO 38, the 2019 European Society for Radiotherapy and Oncology Annual Meeting, held in April in Milan, Italy. The oral presentation, “Single dose high dose-rate (HDR) brachytherapy as monotherapy for localised prostate cancer,” was led by Hannah Tharmalingam, a clinical research fellow at Mount Vernon Cancer Centre, Northwood, and The Christie NHS Foundation Trust, Manchester, U.K. Brachytherapy is a cancer treatment that places small radioactive sources directly into a patient’s tumor, ensuring that the radiation is delivered specifically to cancer cells while it spares healthy surrounding tissues. Usually, this treatment involves the placement of a radioactive seed inside the tumor, which delivers low doses of radiation over time. But prostate cancer patients have another option: a high-dose rate brachytherapy that places the radioactive material temporarily and for shorter periods, while delivering high doses of radiation during that time. The latter approach "usually means patients make four to six visits to the hospital for a series of lower-dose treatments," Tharmalingam said in a
Subscribe or to access all post and page content.